Arch Biopartners Company Insiders

Arch Biopartners Management Team Effectiveness

The company has return on total asset (ROA) of (0.812) % which means that it has lost $0.812 on every $100 spent on assets. This is way below average. Arch Biopartners' management efficiency ratios could be used to measure how well Arch Biopartners manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 14.13 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (2.8 K). At this time, Arch Biopartners' Total Current Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to climb to 0.32 in 2024, whereas Other Current Assets are likely to drop slightly above 39.8 K in 2024. Common Stock Shares Outstanding is likely to drop to about 41.8 M in 2024. Net Loss is likely to drop to about (1.3 M) in 2024

Arch Biopartners Workforce Comparison

The company has Profit Margin (PM) of (1.86) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.39.

Arch Biopartners Benchmark Summation

Arch Biopartners Notable Stakeholders

The success or failure of an entity such as Arch Biopartners often depends on how effective the management is. Arch Biopartners management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Arch management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Arch management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Arch Biopartners' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arch Biopartners. Check Arch Biopartners' Beneish M Score to see the likelihood of Arch Biopartners' management manipulating its earnings.

When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.